Does the media prefer ADPT or ALVO?

In the previous week, Adaptive Biotechnologies had 25 more articles in the media than Alvotech. MarketBeat recorded 31 mentions for Adaptive Biotechnologies and 6 mentions for Alvotech. Alvotech's average media sentiment score of 1.26 beat Adaptive Biotechnologies' score of 0.50 indicating that Alvotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adaptive Biotechnologies 9 Very Positive mention(s) 7 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Alvotech 5 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, OGN or ALVO?

Organon & Co. has higher revenue and earnings than Alvotech. Alvotech is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Organon & Co. $6.13B 0.58 $187M $0.77 17.60 Alvotech $588.90M 2.11 $27.92M -$0.25 N/A

Is OGN or ALVO more profitable?

Organon & Co. has a net margin of 3.41% compared to Alvotech's net margin of -14.36%. Organon & Co.'s return on equity of 92.94% beat Alvotech's return on equity. Company Net Margins Return on Equity Return on Assets Organon & Co. 3.41% 92.94% 6.04% Alvotech -14.36% -11.92% -7.59%

Does the media prefer OGN or ALVO?

In the previous week, Organon & Co. had 6 more articles in the media than Alvotech. MarketBeat recorded 12 mentions for Organon & Co. and 6 mentions for Alvotech. Alvotech's average media sentiment score of 1.26 beat Organon & Co.'s score of 0.59 indicating that Alvotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organon & Co. 5 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alvotech 5 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is LEGN or ALVO more profitable?

Alvotech has a net margin of -14.36% compared to Legend Biotech's net margin of -21.98%. Alvotech's return on equity of -11.92% beat Legend Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Legend Biotech -21.98% -24.92% -14.87% Alvotech -14.36% -11.92% -7.59%

Does the media favor LEGN or ALVO?

In the previous week, Legend Biotech had 9 more articles in the media than Alvotech. MarketBeat recorded 15 mentions for Legend Biotech and 6 mentions for Alvotech. Alvotech's average media sentiment score of 1.26 beat Legend Biotech's score of 0.34 indicating that Alvotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Legend Biotech 5 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Alvotech 5 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ALVO or ARQT?

In the previous week, Arcutis Biotherapeutics had 4 more articles in the media than Alvotech. MarketBeat recorded 10 mentions for Arcutis Biotherapeutics and 6 mentions for Alvotech. Arcutis Biotherapeutics' average media sentiment score of 1.35 beat Alvotech's score of 1.26 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alvotech 5 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arcutis Biotherapeutics 8 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, RLAY or ALVO?

Alvotech has higher revenue and earnings than Relay Therapeutics. Alvotech is trading at a lower price-to-earnings ratio than Relay Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Relay Therapeutics $10.68M 337.91 -$276.48M -$1.57 N/A Alvotech $588.90M 2.11 $27.92M -$0.25 N/A

Does the media prefer RLAY or ALVO?

In the previous week, Relay Therapeutics had 10 more articles in the media than Alvotech. MarketBeat recorded 16 mentions for Relay Therapeutics and 6 mentions for Alvotech. Alvotech's average media sentiment score of 1.26 beat Relay Therapeutics' score of 0.79 indicating that Alvotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relay Therapeutics 10 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Alvotech 5 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Alvotech (ALVO) Competitors

$4.12 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$4.03 -0.09 (-2.31%)

As of 07/31/2026 07:56 PM Eastern

Compare

ALVO vs. ADPT, OGN, LEGN, ARQT, and RLAY

Should you buy Alvotech stock or one of its competitors? MarketBeat compares Alvotech with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Alvotech include Adaptive Biotechnologies (ADPT), Organon & Co. (OGN), Legend Biotech (LEGN), Arcutis Biotherapeutics (ARQT), and Relay Therapeutics (RLAY).

How does Alvotech compare to Adaptive Biotechnologies?

Adaptive Biotechnologies (NASDAQ:ADPT) and Alvotech (NASDAQ:ALVO) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, media sentiment, institutional ownership and profitability.

Alvotech has higher revenue and earnings than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Alvotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adaptive Biotechnologies	$276.98M	13.04	-$59.50M	-$0.41	N/A
Alvotech	$588.90M	2.11	$27.92M	-$0.25	N/A

Adaptive Biotechnologies has a beta of 2.08, indicating that its share price is 108% more volatile than the broader market. Comparatively, Alvotech has a beta of 0.18, indicating that its share price is 82% less volatile than the broader market.

Adaptive Biotechnologies currently has a consensus price target of $23.33, indicating a potential upside of 3.38%. Alvotech has a consensus price target of $7.60, indicating a potential upside of 84.47%. Given Alvotech's higher possible upside, analysts plainly believe Alvotech is more favorable than Adaptive Biotechnologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Alvotech	2 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

Alvotech has a net margin of -14.36% compared to Adaptive Biotechnologies' net margin of -20.73%. Alvotech's return on equity of -11.92% beat Adaptive Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adaptive Biotechnologies	-20.73%	-36.81%	-13.77%
Alvotech	-14.36%	-11.92%	-7.59%

99.2% of Adaptive Biotechnologies shares are held by institutional investors. 5.7% of Adaptive Biotechnologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Adaptive Biotechnologies had 25 more articles in the media than Alvotech. MarketBeat recorded 31 mentions for Adaptive Biotechnologies and 6 mentions for Alvotech. Alvotech's average media sentiment score of 1.26 beat Adaptive Biotechnologies' score of 0.50 indicating that Alvotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adaptive Biotechnologies	9 Very Positive mention(s)	7 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Alvotech	5 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Alvotech beats Adaptive Biotechnologies on 9 of the 16 factors compared between the two stocks.

How does Alvotech compare to Organon & Co.?

Organon & Co. (NYSE:OGN) and Alvotech (NASDAQ:ALVO) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, media sentiment, institutional ownership and valuation.

Organon & Co. presently has a consensus target price of $11.40, indicating a potential downside of 15.90%. Alvotech has a consensus target price of $7.60, indicating a potential upside of 84.47%. Given Alvotech's stronger consensus rating and higher probable upside, analysts clearly believe Alvotech is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71
Alvotech	2 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

77.4% of Organon & Co. shares are held by institutional investors. 1.6% of Organon & Co. shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Organon & Co. had 6 more articles in the media than Alvotech. MarketBeat recorded 12 mentions for Organon & Co. and 6 mentions for Alvotech. Alvotech's average media sentiment score of 1.26 beat Organon & Co.'s score of 0.59 indicating that Alvotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Organon & Co.	5 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alvotech	5 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Organon & Co. has higher revenue and earnings than Alvotech. Alvotech is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organon & Co.	$6.13B	0.58	$187M	$0.77	17.60
Alvotech	$588.90M	2.11	$27.92M	-$0.25	N/A

Organon & Co. has a beta of 1.54, suggesting that its share price is 54% more volatile than the broader market. Comparatively, Alvotech has a beta of 0.18, suggesting that its share price is 82% less volatile than the broader market.

Organon & Co. has a net margin of 3.41% compared to Alvotech's net margin of -14.36%. Organon & Co.'s return on equity of 92.94% beat Alvotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organon & Co.	3.41%	92.94%	6.04%
Alvotech	-14.36%	-11.92%	-7.59%

Summary

Organon & Co. beats Alvotech on 11 of the 16 factors compared between the two stocks.

How does Alvotech compare to Legend Biotech?

Legend Biotech (NASDAQ:LEGN) and Alvotech (NASDAQ:ALVO) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, media sentiment, profitability and institutional ownership.

Legend Biotech has a beta of 0.34, meaning that its stock price is 66% less volatile than the broader market. Comparatively, Alvotech has a beta of 0.18, meaning that its stock price is 82% less volatile than the broader market.

In the previous week, Legend Biotech had 9 more articles in the media than Alvotech. MarketBeat recorded 15 mentions for Legend Biotech and 6 mentions for Alvotech. Alvotech's average media sentiment score of 1.26 beat Legend Biotech's score of 0.34 indicating that Alvotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Legend Biotech	5 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alvotech	5 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alvotech has a net margin of -14.36% compared to Legend Biotech's net margin of -21.98%. Alvotech's return on equity of -11.92% beat Legend Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Legend Biotech	-21.98%	-24.92%	-14.87%
Alvotech	-14.36%	-11.92%	-7.59%

Alvotech has lower revenue, but higher earnings than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Alvotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Legend Biotech	$1.14B	3.03	-$296.80M	-$0.68	N/A
Alvotech	$588.90M	2.11	$27.92M	-$0.25	N/A

Legend Biotech currently has a consensus price target of $55.29, indicating a potential upside of 198.04%. Alvotech has a consensus price target of $7.60, indicating a potential upside of 84.47%. Given Legend Biotech's stronger consensus rating and higher possible upside, research analysts clearly believe Legend Biotech is more favorable than Alvotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Legend Biotech	1 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.53
Alvotech	2 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

70.9% of Legend Biotech shares are held by institutional investors. 0.0% of Legend Biotech shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Legend Biotech beats Alvotech on 9 of the 16 factors compared between the two stocks.

How does Alvotech compare to Arcutis Biotherapeutics?

Alvotech (NASDAQ:ALVO) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, media sentiment, earnings, risk and institutional ownership.

Alvotech presently has a consensus target price of $7.60, suggesting a potential upside of 84.47%. Arcutis Biotherapeutics has a consensus target price of $34.00, suggesting a potential upside of 26.58%. Given Alvotech's higher probable upside, equities analysts clearly believe Alvotech is more favorable than Arcutis Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alvotech	2 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Arcutis Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Arcutis Biotherapeutics had 4 more articles in the media than Alvotech. MarketBeat recorded 10 mentions for Arcutis Biotherapeutics and 6 mentions for Alvotech. Arcutis Biotherapeutics' average media sentiment score of 1.35 beat Alvotech's score of 1.26 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alvotech	5 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arcutis Biotherapeutics	8 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alvotech has higher revenue and earnings than Arcutis Biotherapeutics. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Alvotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alvotech	$588.90M	2.11	$27.92M	-$0.25	N/A
Arcutis Biotherapeutics	$415.62M	8.08	-$16.14M	-$0.03	N/A

Arcutis Biotherapeutics has a net margin of -0.57% compared to Alvotech's net margin of -14.36%. Arcutis Biotherapeutics' return on equity of -1.41% beat Alvotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alvotech	-14.36%	-11.92%	-7.59%
Arcutis Biotherapeutics	-0.57%	-1.41%	-0.59%

Alvotech has a beta of 0.18, suggesting that its share price is 82% less volatile than the broader market. Comparatively, Arcutis Biotherapeutics has a beta of 1.48, suggesting that its share price is 48% more volatile than the broader market.

Summary

Arcutis Biotherapeutics beats Alvotech on 10 of the 14 factors compared between the two stocks.

How does Alvotech compare to Relay Therapeutics?

Relay Therapeutics (NASDAQ:RLAY) and Alvotech (NASDAQ:ALVO) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings.

In the previous week, Relay Therapeutics had 10 more articles in the media than Alvotech. MarketBeat recorded 16 mentions for Relay Therapeutics and 6 mentions for Alvotech. Alvotech's average media sentiment score of 1.26 beat Relay Therapeutics' score of 0.79 indicating that Alvotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relay Therapeutics	10 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Alvotech	5 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Relay Therapeutics has a net margin of 0.00% compared to Alvotech's net margin of -14.36%. Alvotech's return on equity of -11.92% beat Relay Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relay Therapeutics	N/A	-43.94%	-40.11%
Alvotech	-14.36%	-11.92%	-7.59%

Alvotech has higher revenue and earnings than Relay Therapeutics. Alvotech is trading at a lower price-to-earnings ratio than Relay Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relay Therapeutics	$10.68M	337.91	-$276.48M	-$1.57	N/A
Alvotech	$588.90M	2.11	$27.92M	-$0.25	N/A

97.0% of Relay Therapeutics shares are held by institutional investors. 5.0% of Relay Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Relay Therapeutics currently has a consensus target price of $24.92, suggesting a potential upside of 32.32%. Alvotech has a consensus target price of $7.60, suggesting a potential upside of 84.47%. Given Alvotech's higher probable upside, analysts plainly believe Alvotech is more favorable than Relay Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relay Therapeutics	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.86
Alvotech	2 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

Relay Therapeutics has a beta of 1.67, meaning that its stock price is 67% more volatile than the broader market. Comparatively, Alvotech has a beta of 0.18, meaning that its stock price is 82% less volatile than the broader market.

Summary

Relay Therapeutics beats Alvotech on 10 of the 17 factors compared between the two stocks.

Get Alvotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALVO vs. The Competition

Export

Metric	Alvotech	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.24B	$3.54B	$6.85B	$12.42B
Dividend Yield	N/A	3.78%	2.59%	10.03%
P/E Ratio	-16.48	7.38	282.30	24.66
Price / Sales	2.11	1,203.55	564.25	75.48
Price / Cash	18.91	44.80	28.60	46.71
Price / Book	-4.38	16.95	10.98	6.07
Net Income	$27.92M	-$12.56M	$3.49B	$347.99M
7 Day Performance	33.77%	-1.81%	-0.60%	-0.44%
1 Month Performance	14.13%	-8.43%	-5.19%	-4.81%
1 Year Performance	-53.13%	48.41%	62.02%	18.61%

Alvotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALVO Alvotech	3.367 of 5 stars	$4.12 flat	$7.60 +84.5%	-53.1%	$1.24B	$588.90M	N/A	1,460	Positive News Gap Down High Trading Volume
ADPT Adaptive Biotechnologies	1.5928 of 5 stars	$22.49 -0.2%	$20.83 -7.4%	+118.5%	$3.60B	$276.98M	N/A	790	Earnings Report Gap Up
OGN Organon & Co.	2.0656 of 5 stars	$13.54 0.0%	$11.40 -15.8%	+38.9%	$3.55B	$6.16B	14.55	10,000	Upcoming Earnings Dividend Announcement
LEGN Legend Biotech	3.1028 of 5 stars	$19.11 -0.9%	$55.29 +189.4%	-52.2%	$3.55B	$1.14B	N/A	2,965	Upcoming Earnings Gap Down
ARQT Arcutis Biotherapeutics	3.663 of 5 stars	$28.27 +1.6%	$34.00 +20.3%	+88.0%	$3.54B	$415.62M	N/A	150	Positive News Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALVO) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alvotech (ALVO) Competitors

ALVO vs. ADPT, OGN, LEGN, ARQT, and RLAY

How does Alvotech compare to Adaptive Biotechnologies?

Summary

How does Alvotech compare to Organon & Co.?

Summary

How does Alvotech compare to Legend Biotech?

Summary

How does Alvotech compare to Arcutis Biotherapeutics?

Summary

How does Alvotech compare to Relay Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALVO vs. The Competition

Alvotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alvotech (ALVO) Competitors

ALVO vs. ADPT, OGN, LEGN, ARQT, and RLAY

How does Alvotech compare to Adaptive Biotechnologies?

Which has preferable valuation and earnings, ADPT or ALVO?

Which has more volatility and risk, ADPT or ALVO?

Do analysts prefer ADPT or ALVO?

Is ADPT or ALVO more profitable?

Do insiders & institutionals hold more shares of ADPT or ALVO?

Does the media prefer ADPT or ALVO?

Summary

How does Alvotech compare to Organon & Co.?

Do analysts prefer OGN or ALVO?

Do institutionals and insiders believe in OGN or ALVO?

Does the media prefer OGN or ALVO?

Which has better earnings and valuation, OGN or ALVO?

Which has more risk & volatility, OGN or ALVO?

Is OGN or ALVO more profitable?

Summary

How does Alvotech compare to Legend Biotech?

Which has more volatility & risk, LEGN or ALVO?

Does the media favor LEGN or ALVO?

Is LEGN or ALVO more profitable?

Which has preferable valuation & earnings, LEGN or ALVO?

Do analysts recommend LEGN or ALVO?

Do insiders & institutionals have more ownership in LEGN or ALVO?

Summary

How does Alvotech compare to Arcutis Biotherapeutics?

Do analysts recommend ALVO or ARQT?

Does the media favor ALVO or ARQT?

Which has better earnings and valuation, ALVO or ARQT?

Is ALVO or ARQT more profitable?

Which has more volatility and risk, ALVO or ARQT?

Summary

How does Alvotech compare to Relay Therapeutics?

Does the media prefer RLAY or ALVO?

Is RLAY or ALVO more profitable?

Which has stronger earnings & valuation, RLAY or ALVO?

Do institutionals and insiders have more ownership in RLAY or ALVO?

Do analysts rate RLAY or ALVO?

Which has more risk & volatility, RLAY or ALVO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALVO vs. The Competition

Alvotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools